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from viral mediated proof of concept to development of a protein
therapeutic, we determined in rats and rabbits the intraarticular
pharmacokinetics of sFlt01, a VEGF neutralizing Fc fusion protein,
and subsequently the feasibility of sustained release formulation
for prolonging residence time in the joint at or above therapeu-
tic levels for 30∼90 days. N-methyl pyrollidone/poly(lactic acid)
(NMP/PLA) depot is considered here as the formulation strategy.
Methods: Iodinated sFlt01 PK in rat: 65ug 125I-sFlt01 was intraar-
ticularly administered to rat knees 4 weeks after meniscectomy
surgery. Radioactivity of the knee joints was measured at sacriﬁce
1, 6, 24, 72, and 144hrs post injection.
sFlt01 PK in rabbit: 150ug sFlt01 was intraarticularly administered
to rabbit knee 4 weeks after ACL surgery. Rabbits were sacriﬁced
at 6hr, 8hr, 24hr, 18hr, and 48hr post injection. sFlt01 level in
serum, urine, synovial ﬂuid, articular cartilage and synovium was
quantiﬁed by ELISA.
sFlt01 sustained release: NMP/PLA depots were formed by dis-
solving PLA in NMP in a 40:60 w:w ratio. Lyophilized sFlt01 was
added to a concentration of 0.8-1.7 w% and dispersed by son-
ication. Depots were formed by pipetting ∼10ug of material into
PBS, allowing the NMP to dissipate and the depot to solidify. In
vitro release was conducted under physiologic conditions (PBS
+ Tween 20, 37°C). Drug release was quantiﬁed by BCA. VEGF
binding activity was assessed by Biacore and ELISA.
Results: Iodinated sFlt01 PK in rats: The knee joint terminal half
life of sFlt01 is estimated to be 11 hours in OA rats. There is a
very small shift in terminal elimination half life of sFlt01 in joint
between OA rats and non-OA rats.
sFlt01 PK in rabbits: In general, terminal elimination half life of
sFlt01 in joint synovial ﬂuid, synovium and cartilage is very similar
in OA and non-OA groups. Exposure in joint synovial ﬂuid, syn-
ovium, and cartilage is higher in non-OA group than that in OA
group. Systemic exposure in the serum is comparable between
OA and non-OA animals. Absorption of sFlt01 into systemic cir-
culation appears to be very slow. sFlt01 is not detected in urine,
kidney, heart, liver and lung.
sFlt01 sustained release: The NMP/PLA depot showed a nonlinear
release pattern with ∼15% released in 26 days. sFlt01 released
from NMP/PLA depots demonstrated the ability to neutralize VEGF,
as determined by an ELISA assay. Biacore studies showed that
sFlt01 released from NMP-PLA depots lost some capacity to bind
to protein A, indicating modiﬁcation to the Fc portion, but that
captured sFlt01still strongly bound VEGF.
t1/2 (hrs) Synovium Cartilage Synovial Fluid Serum
OA 9.84 7.02 7.77 66.5
Non-OA 9.42 6.19 10.3 71.5
Conclusions: Joint half-life of sFlt01 is as short as hours, sug-
gesting that sustained release formulation is necessary to prolong
sFlt01 residence time in the joint. NMP/PLA depots were shown
to deliver sFlt01 for ∼30 days. New formulations will be in need to
further prolong release, characterize late stage burst and sFlt01
alterations, and to test pharmacokinetics in vivo.
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Purpose: There are no proven therapies that modify the structural
changes in osteoarthritis (OA). Preclinical data suggests that
intra-articular recombinant human Osteogenic Protein-1 (OP-1)
has reparative effects on cartilage, as well as on symptoms of joint
pain. The objective of this study was to determine the safety and
tolerability as well as dose-limiting toxicity and maximal tolerated
dose of intra-articular OP-1. The secondary objectives were to
determine the symptomatic responses through 24 weeks.
Methods: This was a Phase 1, double-blind, randomized, multi-
center, placebo-controlled, single-dose escalation safety study
consisting of 4 dosing cohorts in participants with knee OA. Each
cohort was to consist of 8 treated subjects, with treatment allo-
cation in a 3:1 active (of intra-articular OP-1 (also called BMP-7))
to placebo ratio. Eligible subjects were persons with symptomatic
radiographic knee OA aged over 40 years. The primary objec-
tive of this study was to determine the safety and tolerability
including laboratory assessments, immunogenicity data and ra-
diographic assessments. Secondary objectives were to determine
the proportion of subjects with a 20%, 50%, and 70% improve-
ment in the WOMAC pain and function subscales at 4, 8, 12, and
24 weeks. Other secondary outcomes included the change from
baseline to 4, 8, 12, and 24 weeks for the subscales of the Knee
and Osteoarthritis Outcome Score (KOOS) survey, patient global,
physician global, quality of life from the SF-36 and the OARSI
responder criteria.
Results: The mean age of participants was 60 years and 73%
were female. All 33 subjects who were enrolled completed the
study, most adverse events were mild or moderate and were
similar in placebo and OP-1 groups. The 1mg OP-1 group showed
a higher frequency of injection site pain and there was no ectopic
bone formation seen on plain x-rays. Most subjects in both the
OP-1 and placebo groups experienced a 20% improvement in
pain and by 12 Weeks, the OP-1 group was similar to placebo. In
the participants who received 0.1mg and 0.3mg OP-1, there was
a trend toward greater symptomatic improvement than placebo.
The other secondary endpoints showed similar trends including
the OARSI responder criteria for which the OP-1 groups had more
responders than placebo (see table).
Number (%) of 0.03mg 0.1mg 0.3mg 1mg All Placebo
Responders (N=7) (N=6) (N=6) (N=6) (N=25) (N=8)
Week 4 3 (42.9%) 4 (66.7%) 1 (16.7%) 2 (33.3%) 10 (40%) 1 (12.5%)
Week 8 3 (42.9%) 4 (66.7%) 2 (33.3%) 2 (33.3%) 11 (44%) 0 (0%)
Week 12 1 (14.3%) 4 (66.7%) 2 (33.3%) 1 (16.7%) 8 (32%) 1 (12.5%)
Week 24 1 (14.3%) 5 (83.3%) 2 (33.3%) 1 (20%) 9 (37.5%) 1 (12.5%)
Conclusions: There was no dose limiting toxicity identiﬁed in
this study. The overall trend for OP-1 symptom response was
better than placebo with the 0.1 and 0.3 mg groups. The bell
shaped dose response curve is consistent with pharmacodynamic
studies in pre-clinical models. This symptom response, together
with the lack of dose limiting toxicity provide further support
for the continued development of this product for treatment of
osteoarthritis.
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Purpose: Hyaluronic acid (HA) injections are widely used to treat
knee osteoarthritis (OA). Current evidence on their efﬁcacy, based
on individual trials and meta-analyses, is inconsistent. In the face
